Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Baxter voices satisfaction with Q3 2013 results

Baxter voices satisfaction with Q3 2013 results

18th October 2013

Baxter has published its financial results for the third quarter of 2013, during which it was able to meet its own internal forecasts and expectations.

The company's worldwide sales totalled $3.8 billion (2.35 billion pounds), up by nine percent on Q3 2012, with the recent acquisition of Gambro and the subsequent enhancement of its product portfolio playing a significant role in this growth.

Recent business highlights include the launch of HyQvia, Rixubis, Clinomel and Olimel, as well as regulatory approvals for key products and new collaborations with JW Holdings and Coherus Biosciences.

Baxter's worldwide sales for the first nine months of 2013 now total $10.9 billion, up by four percent year over year.

Robert Parkinson, chairman and chief executive officer of Baxter, said: "Our global presence and diversified healthcare model, together with the advancements we've made to our business portfolio and new product pipeline, are focused on driving improved access to care, better outcomes for patients and enhanced value for our shareholders."

This comes after the company announced the appointment of Todd Young as the new treasurer and corporate officer of Baxter last month, succeeding the outgoing James Saccaro.ADNFCR-8000103-ID-801651249-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.